This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Table of Contents Sr# Headings 1 Introduction: The Pharma Marketing Challenge 2 Building a Winning Pharma Marketing Strategy 3 The Role of Branded Drug Campaigns 4 Innovating for Future Success Introduction: The Pharma Marketing Challenge Marketing pharmaceuticals is no small feat. In an industry where lives are at stake, creating compelling, compliant, and effective campaigns can feel like walking a tightrope.
Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.
The regulatory environment in Japan for generic drug development is complex and has undergone significant changes in recent years. This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Hansa Biopharma has announced positive complete results from its single arm 15-HMedIdeS-09 Phase II study on the use of imlifidase for the treatment of the rare disease Guillain-Barr syndrome (GBS). The company conducted an indirect treatment comparison analysis of 15-HMedIdeS-09 study data to the International Guillain-Barr Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.
(Dave & Les Jacobs/DigitalVision/Getty Images) We know that too much sitting is bad for us, but a new study adds an important detail: if you spend more than 10-and-a-half hours a day sitting or lying down, regular exercise might not be enough to prevent an increased risk of serious heart issues.
A new Fierce Biotech article features insights from Paul Evans on what to expect for clinical research in 2025. Topics include rising costs and uncertain regulations, as well as the continued emergence of site networks, AI-driven efficiency (with technology built by trial sites, for trial sites), and enhanced diversity initiatives. Read the article here: [link] The post Fierce Biotech Article: Paul Evans on Clinical Trials in 2025 appeared first on Velocity Clinical Research.
A new Fierce Biotech article features insights from Paul Evans on what to expect for clinical research in 2025. Topics include rising costs and uncertain regulations, as well as the continued emergence of site networks, AI-driven efficiency (with technology built by trial sites, for trial sites), and enhanced diversity initiatives. Read the article here: [link] The post Fierce Biotech Article: Paul Evans on Clinical Trials in 2025 appeared first on Velocity Clinical Research.
Learn how digital biomarkers are revolutionising respiratory care by providing personalised, real-time data for better monitoring and management of respiratory diseases.
The Central Drugs Standard Control Organisation (CDSCO) has sought the industry to start submitting the applications for clinical trial site addition and change of principal investigator through online mode, as part of streamlining the regulatory submission procedure.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Anteris Technologies Global Corp. (ATGC) has gone public with its initial public offering (IPO), marking a significant milestone in its journey to transform the heart valve market. The company offered 14.8 million shares of its common stock at an initial price of $6.00 per share. Trading began on the Nasdaq Global Market on December 13, 2024, under the ticker symbol “AVR,” with the offering closed on December 16, 2024.
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.
Boston Scientific has issued an urgent recall of some of its Accolade pacemakers following reports of malfunctions that have been tied to two patient deaths. The company said the recall affects a subset of Accolade pacemakers, which include Proponent, Essentio and Altrua 2 dual chamber (DR) standard life (SL) and R extended life (EL) pacemakers. Also included are the Visionist and Valtitude cardiac resynchronization therapy pacemakers (CRT-Ps).
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end of recent annual tallies.
Viatris Inc. has announced promising Phase IIb results for cenerimod, an investigational drug targeting immune system dysfunction in moderate-to-severe systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system attacks healthy tissues, causing inflammation, pain and potential organ damage. Cenerimod modulates the immune response, reducing inflammation and preventing the production of harmful autoantibodies.
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The challenges facing oncology clinical trials are multifaceted, but there is a clear opportunity for pharmaceutical companies to rethink their approach to clinical research, and prioritise the patient from the beginning.
University of Arizona researchers have revealed new insights into one of the most common complications faced by Parkinson's disease patients: uncontrollable movements that develop after years of treatment.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The AI revolution in pharma and biotech is transforming the healthcare industry. Discover how artificial intelligence is revolutionising drug discovery, precision medicine, and patient care.
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that often resides on the surface of immune system cells, the PD-1 molecule works as a type of "off" switch that keeps immune cells from attacking other cells.
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Research Center: UVA Health with Myriad Genetics Location: This is a study recruiting in Virginia and Maryland Lead Researcher: Dr. Jennifer L. Payne IRB: This study has been reviewed and approved by the University of Virginia Institutional Review Board HSR230396 About the Study How does pregnancy affect the way antidepressants work?
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content